
Bilal Chughtai, MD, discusses cystoscopic outcomes with the Zenflow Spring System
Bilal I. Chughtai, MD, highlights 12-month cystoscopic data from the pivotal IDE trial of the Zenflow Spring System.
In the following video, Bilal I. Chughtai, MD, highlights 12-month cystoscopic data from the pivotal IDE trial of the Zenflow Spring System. These findings were presented at the
Chughtai is the chief of urology at Plainview Hospital in Syosset, New York.
The Zenflow Spring System is a minimally invasive implant that was granted clearance in December 2025 for the management of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). The device is composed of nitinol and was designed to minimize device removal due to encrustation and/or migration, which was a challenge with past prostatic urethral stents.
The findings presented at AUA 2026 focused on 12-month cystoscopic outcomes from the pivotal study of the Zenflow implant. Of 162 patients included in the safety and roll-in populations, 136 underwent cystoscopic evaluation at 12 months. Investigators assessed implant position, biofilm formation, encrustation, and edema using a grading system reviewed by independent urologists.
The analysis showed no statistically significant negative impact on efficacy outcomes, including IPSS total score, change from baseline in IPSS, or responder rates, based on implant position or the presence of minor biofilm, minor encrustation, or edema. Minor biofilm was observed in 6 patients and minor encrustation in 7 patients. Only 1 patient demonstrated significant edema. Importantly, no major encrustation events were observed, and there was no evidence that implants migrated to interfere with the external urethral sphincter.
According to Chughtai, the cystoscopic findings reinforce the long-term durability and biocompatibility of the implant.
REFERENCE
1. Chughtai B, Jakubowicz D, Mazzarella B, et al. LONGITUDINAL CYSTOSCOPIC EVALUATION OF A NEXT GENERATION PROSTATIC URETHRAL IMPLANT: EVALUATION OVER 12 MONTHS. J Urol. 2026;215(5S):e1092. doi:10.1097/01.JU.0001191600.08337.62.20











